Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)
by Doug Wharley · The Cerbat GemTeva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors acquired 17,205 call options on the stock. This represents an increase of approximately 44% compared to the typical daily volume of 11,916 call options.
Insider Buying and Selling at Teva Pharmaceutical Industries
In other news, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the transaction, the executive vice president owned 85,755 shares in the company, valued at $2,715,860.85. This trade represents a 16.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the transaction, the insider owned 224,940 shares in the company, valued at $6,779,691.60. This represents a 21.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 920,901 shares of company stock worth $30,056,789. Insiders own 0.54% of the company’s stock.
Institutional Trading of Teva Pharmaceutical Industries
Hedge funds have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter worth $25,000. Allworth Financial LP lifted its stake in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares in the last quarter. Grove Bank & Trust lifted its stake in Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after purchasing an additional 345 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Teva Pharmaceutical Industries by 567.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock worth $42,000 after purchasing an additional 1,134 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.
Wall Street Analysts Forecast Growth
TEVA has been the topic of several recent analyst reports. Jefferies Financial Group raised their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Truist Financial raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday. The Goldman Sachs Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Scotiabank raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $41.56.
Read Our Latest Report on TEVA
Teva Pharmaceutical Industries Price Performance
Shares of TEVA stock traded down $0.03 on Friday, hitting $35.04. 382,071 shares of the stock traded hands, compared to its average volume of 8,227,239. The firm has a market cap of $40.29 billion, a price-to-earnings ratio of 26.35, a PEG ratio of 3.12 and a beta of 0.76. Teva Pharmaceutical Industries has a 52 week low of $14.99 and a 52 week high of $37.35. The firm has a 50 day simple moving average of $31.15 and a two-hundred day simple moving average of $29.33. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 44.86%. As a group, equities research analysts predict that Teva Pharmaceutical Industries will post 2.6 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries News Roundup
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
- Positive Sentiment: Q1 results beat estimates — revenue and EPS topped forecasts as branded drugs (Austedo, Ajovy, Uzedy) drove growth, improving investor confidence despite mixed generics trends. TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up
- Positive Sentiment: Teva agreed to acquire Emalex Biosciences to add a late‑stage, NDA‑ready neuroscience asset (ecopipam for pediatric Tourette’s) — a deal viewed as strategic to expand the innovative pipeline and revenue runway. Reports cite upfront and milestone payments (structure reported around $700M–$900M, with additional contingent payments). Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
- Positive Sentiment: Multiple analyst upgrades and price-target raises: Truist raised its target to $45 (buy), UBS to $42 (buy), JPMorgan to $40 (overweight), and Piper Sandler reaffirmed overweight and nudged its target — signaling institutional conviction and creating further upside expectations. Analyst Price-Target Upgrades Coverage
- Positive Sentiment: Private capital interest — reports of a $400M financing commitment from Blackstone reinforce confidence in Teva’s strategic pivot and capital structure flexibility. Blackstone’s $400 Million Bet on Teva
- Positive Sentiment: ESG progress — Teva says it met all targets tied to sustainability‑linked bonds, which lowers financing risk on ~$7.5B of linked debt and supports investor sentiment on capital allocation. Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress
- Positive Sentiment: Unusually heavy call-option activity ahead of/around results suggests bullish speculative positioning and amplified upside volatility. (Market data reported unusually large call purchases.)
- Neutral Sentiment: Analyst commentary and valuation pieces note Teva could be re‑rated if growth from branded drugs and M&A continues; valuation now under renewed scrutiny after the Q1 reaction. Teva Positioned for Re-Rating on Growth Drivers, UBS Says
- Neutral Sentiment: Industry positioning — Teva is named among leaders in a growing oral solid dosage contract‑manufacturing market, which supports longer‑term services/resilience but is not an immediate revenue lever. Analysis of the 2026 Oral Solid Dosage Contract Manufacturing Market
- Negative Sentiment: Generics pressure — management flagged weaker generics revenue (including lower sales from lenalidomide capsules), which offsets some of the branded upside and keeps execution risks on the table. TEVA Q1 Earnings Top Estimates — Branded Drugs Drive Revenues, Stock Up
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.